1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

  • March 2019
  • 164 pages
  • ID: 5790641
  • Format: PDF
  • GlobalData


Table of Contents

Search Inside

Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027

The Multiple Myeloma (MM) market is expected to grow from $14.5bn in 2017 to $27.8bn by 2027 across the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, and China) at a compound annual growth rate (CAGR) of 6.7%. The modest growth of the Multiple Myeloma (MM) market will be driven by increasing prevalence, primarily by aging populations, as well as the approval and launch of new branded therapies. In addition, label expansion of currently marketed therapies: Darzalex, Kyprolis, Pomalyst, Ninlaro, and Empliciti will promote market growth during the forecast period.

BCMA-targeting class of therapies is highly anticipated in Multiple Myeloma (MM) and they are expected to improve treatment outcome in heavily-treated patients, an area of major unmet need in Multiple Myeloma (MM).It is expected to result in significant revenues due to premium pricing and clinical benefit in heavily pretreated patients.

This class will be represented by four drug candidates, BCMA CAR-Ts bb2121 and JNJ-4528, the bispecific T-cell engager AMG 420, and the antibody-drug conjugate GSK2857916. The combined revenue of all four therapies is expected to reach $10bn in 2027.

Generic and biosimilar erosion of some of the mainstays of Multiple Myeloma (MM) treatment is also expected between 2017 and 2027.A major barrier for market growth in Multiple Myeloma (MM) will be the increased use of generics, in particular generic lenalidomide.

The branded Revlimid alone brought in around $6.1bn in the US in 2018. Patent expiry is also expected for other major current standards of treatment, Velcade, Kyprolis, Pomalyst, Ninlaro, and Darzalex, during the forecast period. Generic and biosimilar erosion is expected to temper market growth significantly.

The company’s latest report, ‘Multiple Myeloma: Global Drug Forecast and Market Analysis to 2027’, states that the main driver of growth in the global Multiple Myeloma (MM) market for the next ten years will be the approval and launch of pipeline therapies in multiple treatment lines.

Key Questions Answered by the report -

- Which pipeline agents are the most promising and expected to launch in the 8 major markets? What are the forecasted sales of these agents and what will be their impact in the Multiple Myeloma (MM) market?
- What are the main unmet needs in Multiple Myeloma (MM), which pipeline drugs will fulfill these needs, and to what extent?
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
- Key Opinions Leaders (KOLs) insights across the 8 major markets, relating to the current treatment options and opinions on the late and early stage pipeline agents.

- Overview of MM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized MM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027. Hybrid forecast model: incidence & prevalence.
- Key topics covered include strategic competitive assessment, market characterization, unmet needs, clinical trial mapping and implications for the MM therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MM. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global MM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MM market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Radiotherapy Market – Analysis By Procedure (External Radiation, Internal Radiation), Product, Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)

  • $ 2400
  • July 2021
  • 240 pages

Executive Summary Global Radiotherapy Market was valued at USD 7987.01 Million in the year 2020. Increasing healthcare expenditure on the back of growing disposable income, rapid technological advancements ...

  • World
  • Cancer
  • Specialty Hospital
  • Industry analysis
  • Cancer Incidence
  • Health Expenditure


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on